Ullrich Graeven
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ullrich Graeven has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Dominik Paul Modest
Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
31 shared publications - Sebastian Stintzing
Department of Hematology, Oncology and Cancer Immunology, Charité—Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
31 shared publications - Volker Heinemann
Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany
31 shared publications - Arndt Stahler
Department of Hematology, Oncology and Cancer Immunology (CCM), Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Berlin, Germany
30 shared publications - Annika Kurreck
Charité-Universitätsmedizin Berlin 9 Department of Hematology, Oncology, and Cancer Immunology Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
29 shared publications - Lothar Müller
Oncology Practice UnterEms, Leer, Germany
28 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Purpose:KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood.Experimental Design:In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed.Results:The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months.Conclusions:KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Purpose:KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood.Experimental Design:In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed.Results:The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months.Conclusions:KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S2: Kaplan-Meier statistics on median real-world overall survival (rwOS) in different subgroups
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S2: Kaplan-Meier statistics on median real-world overall survival (rwOS) in different subgroups
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S3: In support of Fig. 5: PD-L1 expression in the different therapy subgroups
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S3: In support of Fig. 5: PD-L1 expression in the different therapy subgroups
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S1: Localization of genetic co-alterations (Created with cBioPortal [Scheffler M][https://www.cbioportal.org])
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Supplementary Figure S1: Localization of genetic co-alterations (Created with cBioPortal [Scheffler M][https://www.cbioportal.org])
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (1) , 31-41
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
PURPOSE: Consensus molecular subtypes (CMSs) of metastatic colorectal cancer (mCRC) are debatable biomarkers. An individual patient data (IPD) meta-analysis was performed to test for impact on objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS), and treatment interaction. METHODS: IPD ( RAS wild-type [WT] tumors treated per protocol [fluorouracil/capecitabine, irinotecan/oxaliplatin, anti–vascular endothelial growth factor {VEGF}/anti–epidermal growth factor receptor {EGFR} antibodies] and with evaluable CMSs) were collected from five trials identified in PubMed, Embase, Medline, Cochrane Library, and proceedings of ASCO/European Society for Medical Oncology: FIRE1 (no identifier), FIRE3 (ClinicalTrials.gov identifier: NCT00433927 ), XELAVIRI (ClinicalTrials.gov identifier: NCT01249638 ), PanaMa (ClinicalTrials.gov identifier: NCT01991873 ), and TRIBE2 (ClinicalTrials.gov identifier: NCT02339116 ). The one-step IPD meta-analysis approach assessed data taking the clustering of patients in the studies into account (ORR: generalized estimating equations models; PFS/OS: Cox models). RESULTS: Seven hundred ninety patients were included: CMS1, n = 77 (9.7%); CMS2, n = 345 (43.7%); CMS3, n = 74 (9.4%); and CMS4, n = 294 (37.2%). Between-study heterogeneity was negligible (variance < 1 × 10 −6 ). Compared with CMS1, CMS2 and CMS4 tumors had numerically higher odds ratios (OR) for ORR (CMS2: OR, 1.668 [95% CI, 0.982 to 2.836]; P = .059; CMS4: OR, 1.369 [95% CI, 0.874 to 2.146]; P = .170), and longer PFS (CMS2: hazard ratios [HR], 0.64 [95% CI, 0.48 to 0.85]; P = .002; CMS4: HR, 0.67 [95% CI, 0.50 to 0.91]; P = .009) and OS (CMS2: HR, 0.59 [95% CI, 0.43 to 0.80]; P < .001; CMS4: HR, 0.67 [95% CI, 0.49 to 0.92]; P = .01). The use of anti-EGFR versus anti-VEGF antibodies meaningfully improved PFS (HR, 0.67 [95% CI, 0.46 to 0.97]; P = .03) and OS (HR, 0.49 [95% CI, 0.33 to 0.72]; P < .001) in CMS4 tumors and was consistently observed for CMS4 RAS / BRAF WT (HR, 0.55 [95% CI, 0.37 to 0.83]; P = .004) or microsatellite stable status (HR, 0.52 [95% CI, 0.32 to 0.86]; P = .01). The interaction test of antibody treatment with CMSs was significant for PFS ( P < .001) and OS ( P < .001) in all patients and for OS in patients with RAS / BRAF WT tumors ( P = .02). CONCLUSION: CMS4 might be an additional biomarker of anti-EGFR treatment efficacy in RAS (and BRAF ) WT mCRC.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (1) , 31-41
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer
PURPOSE: Consensus molecular subtypes (CMSs) of metastatic colorectal cancer (mCRC) are debatable biomarkers. An individual patient data (IPD) meta-analysis was performed to test for impact on objective response rates (ORRs), progression-free survival (PFS) and overall survival (OS), and treatment interaction. METHODS: IPD ( RAS wild-type [WT] tumors treated per protocol [fluorouracil/capecitabine, irinotecan/oxaliplatin, anti–vascular endothelial growth factor {VEGF}/anti–epidermal growth factor receptor {EGFR} antibodies] and with evaluable CMSs) were collected from five trials identified in PubMed, Embase, Medline, Cochrane Library, and proceedings of ASCO/European Society for Medical Oncology: FIRE1 (no identifier), FIRE3 (ClinicalTrials.gov identifier: NCT00433927 ), XELAVIRI (ClinicalTrials.gov identifier: NCT01249638 ), PanaMa (ClinicalTrials.gov identifier: NCT01991873 ), and TRIBE2 (ClinicalTrials.gov identifier: NCT02339116 ). The one-step IPD meta-analysis approach assessed data taking the clustering of patients in the studies into account (ORR: generalized estimating equations models; PFS/OS: Cox models). RESULTS: Seven hundred ninety patients were included: CMS1, n = 77 (9.7%); CMS2, n = 345 (43.7%); CMS3, n = 74 (9.4%); and CMS4, n = 294 (37.2%). Between-study heterogeneity was negligible (variance < 1 × 10 −6 ). Compared with CMS1, CMS2 and CMS4 tumors had numerically higher odds ratios (OR) for ORR (CMS2: OR, 1.668 [95% CI, 0.982 to 2.836]; P = .059; CMS4: OR, 1.369 [95% CI, 0.874 to 2.146]; P = .170), and longer PFS (CMS2: hazard ratios [HR], 0.64 [95% CI, 0.48 to 0.85]; P = .002; CMS4: HR, 0.67 [95% CI, 0.50 to 0.91]; P = .009) and OS (CMS2: HR, 0.59 [95% CI, 0.43 to 0.80]; P < .001; CMS4: HR, 0.67 [95% CI, 0.49 to 0.92]; P = .01). The use of anti-EGFR versus anti-VEGF antibodies meaningfully improved PFS (HR, 0.67 [95% CI, 0.46 to 0.97]; P = .03) and OS (HR, 0.49 [95% CI, 0.33 to 0.72]; P < .001) in CMS4 tumors and was consistently observed for CMS4 RAS / BRAF WT (HR, 0.55 [95% CI, 0.37 to 0.83]; P = .004) or microsatellite stable status (HR, 0.52 [95% CI, 0.32 to 0.86]; P = .01). The interaction test of antibody treatment with CMSs was significant for PFS ( P < .001) and OS ( P < .001) in all patients and for OS in patients with RAS / BRAF WT tumors ( P = .02). CONCLUSION: CMS4 might be an additional biomarker of anti-EGFR treatment efficacy in RAS (and BRAF ) WT mCRC.
- 19 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (10) , 2110-2119
Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Purpose: KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood. Experimental Design: In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed. Results: The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months. Conclusions: KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.
- 19 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (10) , 2110-2119
Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations
Purpose: KRAS G12V is among the most frequent KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical and molecular features remain poorly understood. Experimental Design: In this retrospective study, we analyzed 636 patients with KRAS G12V–mutated NSCLC diagnosed between 2018 and 2023. Clinical, pathologic, and molecular characteristics, including co-mutations, smoking history, programmed cell death ligand 1 (PD-L1) expression, CD8+ T-cell infiltration, and treatment outcomes, were assessed. Results: The majority of patients (94.2%) were current or former smokers, with a median tobacco exposure of 40 pack-years. Co-mutations were frequent, most commonly in TP53 (40.2%), STK11 (30.2%), and KEAP1 (29.3%). Heavy smokers exhibited significantly higher PD-L1 expression and more frequent TP53, KEAP1, and NTRK1–3 mutations than light smokers. CD8+ T-cell infiltration showed a nonsignificant trend toward higher values in G12V compared with non-G12V KRAS subtypes. Among 151 patients with advanced disease, those treated with immune checkpoint blockade (ICB) alone or in combination with chemotherapy had significantly higher response rates and improved real-world progression-free survival and real-world overall survival (rwOS) compared with chemotherapy alone. In patients with PD-L1 tumor proportion score ≥50%, ICB-based treatment achieved a median rwOS of 30 months. Conclusions: KRAS G12V–mutated NSCLC is characterized by a strong association with tobacco use, high co-mutation rates in clinically relevant genes, and a favorable response to PD-L1–based immunotherapy. The observed mutation landscape supports the potential for dual checkpoint blockade in a significant subset.
- Open Access
- 18 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8935
Patient Characteristics and Different Decision Paths for Establishing Palliative Care for Patients Admitted via the Emergency Department
Background: Up to 10% of emergency department (ED) patients present with palliative care needs. Despite rising demand for palliative expertise in acute care, ED processes for these patients remain heterogeneous, and data from German EDs are limited. Methods: This retrospective cohort study included all patients presenting to the ED of a 754-bed academic hospital in 2023 who were later admitted to the palliative care ward. Demographics, symptom burden at ED and palliative care admission, length of stay (LOS), and discharge outcomes were analyzed after ethics approval (EK 24-062). Patients transferred to palliative care later during hospitalization (group 1) were compared with those directly transferred after ED treatment (group 2). Results: Among 229 included patients, 190 were identified as group 1 and 39 as group 2 patients. Demographics and cancer prevalence were comparable (68.4% vs. 69.2%). In group 1, fatigue, neurological symptoms, dyspnea, and anxiety/restlessness significantly increased during hospitalization, while anxiety/restlessness decreased significantly in group 2. Before palliative admission, LOS in group 1 was 15.2 ± 13.9 days; 36.8% required intensive or stroke unit care. LOS in the palliative ward (8.0 ± 6.6 vs. 9.3 ± 10.3 days, p = 0.45) and discharge alive rates (27.1% both groups) did not differ. Conclusions: Early recognition and management of palliative needs in the ED may reduce symptom burden. Once specialized palliative care was established, LOS and mortality were comparable across groups, highlighting the value of standardized assessments for early identification and integration of palliative care in acute settings.
- 18 December 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (24) , 8935
Open AccessPatient Characteristics and Different Decision Paths for Establishing Palliative Care for Patients Admitted via the Emergency Department
Background: Up to 10% of emergency department (ED) patients present with palliative care needs. Despite rising demand for palliative expertise in acute care, ED processes for these patients remain heterogeneous, and data from German EDs are limited. Methods: This retrospective cohort study included all patients presenting to the ED of a 754-bed academic hospital in 2023 who were later admitted to the palliative care ward. Demographics, symptom burden at ED and palliative care admission, length of stay (LOS), and discharge outcomes were analyzed after ethics approval (EK 24-062). Patients transferred to palliative care later during hospitalization (group 1) were compared with those directly transferred after ED treatment (group 2). Results: Among 229 included patients, 190 were identified as group 1 and 39 as group 2 patients. Demographics and cancer prevalence were comparable (68.4% vs. 69.2%). In group 1, fatigue, neurological symptoms, dyspnea, and anxiety/restlessness significantly increased during hospitalization, while anxiety/restlessness decreased significantly in group 2. Before palliative admission, LOS in group 1 was 15.2 ± 13.9 days; 36.8% required intensive or stroke unit care. LOS in the palliative ward (8.0 ± 6.6 vs. 9.3 ± 10.3 days, p = 0.45) and discharge alive rates (27.1% both groups) did not differ. Conclusions: Early recognition and management of palliative needs in the ED may reduce symptom burden. Once specialized palliative care was established, LOS and mortality were comparable across groups, highlighting the value of standardized assessments for early identification and integration of palliative care in acute settings.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Overview of antibodies used for staining and cutoffs in TMA analysis.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Overview of antibodies used for staining and cutoffs in TMA analysis.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.